Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

NCT03895567 | Suspended Phase 1 DMC

• 1 other identifier: BAC18003
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults. The following regimens will be evaluated in random order in all participants: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg) Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised. This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Bioavailablity of rectal formulation

  Approximately 9 months

Secondary Outcomes (6)

• Description of Exposure (AUC0-∞)

  Approximately 9 months

• Description of Peak concentration (Cmax)

  Approximately 100 days

• Description of Absorption rate (Tmax)

  Approximately 9 months

• Time above a plasma concentration of 1µg/mL (this concentration is above the MIC90 for major neonatal pathogens and is the lower limit of detection of the assay)

  Approximately 9 months

• Occurrence of serious adverse events (SAEs) from the date of the first dose to 28 days after the final dose, according to the MedDRA classification.

  Approximately 9 months

Study Arms (6)

ABC

EXPERIMENTAL

A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

ACB

EXPERIMENTAL

A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

BAC

EXPERIMENTAL

B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

BCA

EXPERIMENTAL

B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

CAB

EXPERIMENTAL

C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

CBA

EXPERIMENTAL

C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)

Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection); Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg); Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

Interventions

A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) DRUG

Parenteral ceftriaxone Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

ABC; ACB; BAC; BCA; CAB; CBA

B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) DRUG

Rectal ceftriaxone formulations Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

ABC; ACB; BAC; BCA; CAB; CBA

C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) DRUG

Rectal ceftriaxone formulations Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet

ABC; ACB; BAC; BCA; CAB; CBA

Eligibility Criteria

• Age: 18 Years - 46 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or non-pregnant female, aged 18 to 46 years (inclusive)
• Willing and able to give informed consent to participate in the trial
• Able, in the investigators opinion, and willing to comply with the study requirements and followup.

You may not qualify if:

• Female participant who is pregnant, lactating or planning pregnancy during the course of the study.
• Presence of any condition which in the judgment of the investigator would affect the absorption of the rectal formulation e.g. previous surgery, haemorrhoids, inflammatory bowel disease
• Irritable bowel syndrome (IBS) or diarrhoea in the 24 hours prior to study drug administration
• Presence of any condition which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition).
• Seropositive for HIV at screening
• Hepatitis B surface antigen (HBsAg) detected in serum at screening.
• Seropositive for hepatitis C virus (antibodies to HCV) at screening
• Participation in a clinical trial and/or has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication and throughout the study period.
• Any medical condition that in the judgment of the investigator would make the administration of the study treatments unsafe.
• Use of medications known to have a potentially clinically significant interaction with ceftriaxone or with sodium chenodeoxycholate (Na-CDC) in the 28 days prior to the first dose and throughout the study period. This includes aluminium-containing antacids, colestipol, phenobarbital and the combined oral contraceptive pill.
• Known 27-hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis)
• History of anaphylaxis and /or hypotension, laryngeal oedema, wheezing, angioedema or urticarial rash following treatment with ceftriaxone, another cephalosporin or any beta lactam (e.g. penicillin).
• History of any other clinically significant reaction to ceftriaxone, another cephalosporin or beta lactam e.g. drug induced nephritis, hepatitis, erythema multiforme that, in the opinion of the investigator, contraindicates participation in the study.
• Serious chronic illness.
• Abnormal baseline laboratory screening test as defined below:

Sponsors & Collaborators

• University of Oxford: lead
• Biopharma (Orofino Pharmaceuticals Group): collaborator

Study Sites (1)

Faculty of Tropical Medicine, Mahidol University

Bangkok, Bangkok, 10400, Thailand

Location

Study Officials

• Elizabeth Ashley, MD

  Mahidol Oxford Tropical Medicine Research Unit

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2019
• First Posted: March 29, 2019
• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: December 26, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Access Criteria: Requests to share data will be considered by the MORU data access committee in line with the MORU data sharing policy

Locations

TH (1)